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Alpha-1 antitrypsin (AAT) deficiency is well-suited as a target for
human gene transfer. We performed a phase 1, open-label, dose-
escalation clinical trial of a recombinant adeno-associated virus
(rAAV) vector expressing normal (M) AAT packaged into serotype 1
AAV capsids delivered by i.m. injection. Nine AAT-deficient subjects
were enrolled sequentially in cohorts of 3 each at doses of 6.9 1012,
2.2  1013, and 6.0  1013 vector genome particles per patient. Four
subjects receiving AAT protein augmentation discontinued therapy
28or 56daysbefore vector administration. Vector administrationwas
well tolerated, with only mild local reactions and 1 unrelated serious
adverse event (bacterial epididymitis). There were no changes in
hematology or clinical chemistry parameters. M-specific AAT was
expressedabovebackground inall subjects in cohorts 2and3andwas
sustained at levels 0.1% of normal for at least 1 year in the highest
dosage level cohort, despite development of neutralizing antibody
and IFN- enzyme-linked immunospot responses to AAV1 capsid at
day 14 in all subjects. These findings suggest that immune responses
to AAV capsid that develop after i.m. injection of a serotype 1 rAAV
vector expressing AAT do not completely eliminate transduced cells
in this context.
AAV  CTL  immune response  pulmonary  gene therapy
A lpha-1 antitrypsin (AAT) deficiency is among the most com-mon single gene disorders in North America and Northern
Europe, with a mutant allele frequency of up to 4% (1, 2). It is
inherited as a codominant disorder with variable penetrance.
Normal serum AAT levels range from 20 to 53 M, and AAT-
deficient individuals with plasma AAT levels11 M are prone to
spontaneous development of chronic lung disease, characterized by
airway inflammation and panacinar emphysema. More than 95% of
deficient alleles are of one particular proteinase inhibitor (PI)
phenotype, known as PI*Z (glu342lys) (3, 4). Heterozygous carriers
with 1 PI*Z allele and 1 wild-type (PI*M) allele may also have an
increased risk of lung disease if they are exposed to tobacco smoke
or other detrimental environmental factors (5). It is generally
accepted that AAT lung disease is caused by a lack of normal
function of AAT as the principal plasma antiprotease, and the only
currently available treatment is protein augmentation therapy using
AAT purified from normal human donor plasma (6). However,
protein augmentation therapy is suboptimal because of the need for
weekly i.v. infusions, high cost, and limited availability.
On the basis of these considerations, recent attempts at AAT
gene therapy have focused on gene augmentation through i.m.
administration of recombinant adeno-associated virus (rAAV)
vectors, which are capable of long-term transduction of skeletal
myofibers in mice, with sustained secretion of plasma proteins, such
as AAT, erythropoietin, or factor IX (7–10). A previous phase 1
trial of i.m. rAAV–AAT based on the well-studied AAV serotype
2 showed favorable safety characteristics, but transgene expression
was only barely above background transiently in 1 of 12 subjects
(11). Because of a marked efficiency advantage for vectors pack-
aged in AAV serotype 1 capsid and injected in murine muscle, our
group proceeded with preclinical development of a cross-packaged
or pseudotyped rAAV–AAT vector, using the same rAAV–AAT
gene cassette as in the previous clinical trial but packaged in a
serotype 1 capsid (10, 12, 13).
Recent data from other clinical programs attempting to use
rAAV vectors to augment plasma proteins have raised the possi-
bility that a fundamental limitation to this approach may be posed
by immune responses to the AAV capsid. In a recent trial of
rAAV2–factor IX delivered by hepatic artery injection, 1 subject
developed a transient rise in transaminases concurrent with a loss
of transgene expression, whereas a second subject showed transient
expression of factor IX without transaminase elevations. A third
subject demonstrated transient elevations in transaminases, which
correlated with the appearance of T cells specific for the AAV2
capsid without detectable factor IX (cells were not available from
the first 2 subjects to evaluate the time course of T cell activation)
(14). Although it is unclear how this observation might relate to
other AAV serotype capsids and other routes of administration,
preliminary results of a rAAV1–lipoprotein lipase (LPL) trial
raised the possibility that such a mechanism might be generalized
to i.m. delivery of different serotypes, based on the demonstration
of capsid-specific T cells concurrent with a transient rise in serum
creatine kinase (CK) and a reversal of a decline in serum triglyc-
erides (an indirect measure of LPL expression) in 1 subject (15).
In the present study, 9 AAT-deficient (PI*ZZ) individuals were
dosed sequentially in cohorts of 3, each receiving i.m. doses of 6.9
1012, 2.2  1013, or 6.0  1013 vector genome particles (vg), and
immune responses were monitored by IFN- enzyme-linked im-
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munospot (ELISPOT), lymphocyte proliferation, and serum anti-
body responses to AAV1 capsid and the AAT transgene. ELISPOT
assays were performed prospectively in the last 5 subjects in the trial
and retrospectively in others. All other assays were performed
prospectively in all patients, as were general safety assessments,
serum CK measurements, and assays for transgene expression.
These studies have enabled a prospective analysis of the relation-
ship between immune responses to capsid and sustained transgene
expression, and have supported the concept that immune responses
to the rAAV1–AAT vector do not completely eliminate transduced
muscle cells in this context.
Results
Characteristics of the Study Population. All study subjects were
enrolled at the University of Florida under a protocol approved by
the Western Institutional Review Board and reviewed by an
executive group of the University of Florida Institutional Review
Board and the gene therapy Data and Safety Monitoring Board of
the National Heart, Lung, and Blood Institute. An Investigational
New Drug Application sponsored by Applied Genetic Technologies
Corporation was filed with the U.S. Food and Drug Administration.
Informed consent was obtained from each subject, and a decision
monitoring protocol was used to ensure that subjects understood
the risks of the protocol and the anticipated lack of clinical benefit
from their participation.
The study population consisted of 9 subjects (5 male, 4 female)
who had been diagnosed as homozygous for PI*Z with a serum
AAT level11 M. The demographic and baseline characteristics
of the subjects are presented in Table 1. Four subjects had received
a serotype 2 AAV–AAT vector in a prior gene transfer study (11).
Four subjects were receiving weekly AAT protein augmentation
therapy, which was discontinued 28 days (subjects 102 and 103) or
56 days (subjects 201 and 303) before administration of rAAV1–
AAT and resumed after the day-90 visit. Subjects were enrolled
sequentially into 1 of 3 dosage level cohorts of 6.9 1012, 2.2 1013,
or 6.0 1013 vg administered by i.m. injection in a total volume of
9.9 mL.
General Safety and Biodistribution. Each subject underwent exten-
sive clinical and laboratory monitoring at baseline and for 1 year
after study agent administration. Minor adverse events were occa-
sionally observed, but the only such events related to the study agent
were minimal to mild reactions at the injection site in 7 of 9 subjects
(bruising in 6, swelling or induration in 3, redness in 2, and warmth
or tenderness in 1 each) that were not considered clinically impor-
tant. Only 1 serious adverse event was reported, a culture-proven
Escherichia coli epididymitis with onset 21⁄2 weeks after vector
administration that was judged unrelated to vector administration.
There were no clinically important changes in hematology, serum
chemistry, or urinalysis parameters after vector administration.
Biodistribution studies demonstrated vector DNA in the blood in
2 of 3 subjects in each of the 2 lower dose cohorts and 3 of 3 subjects
in the highest dose cohort, which was maximal at day 1 and
progressively decreased to become negative by day 14 or day 90 in
all but 1 subject (supporting information Table S1). No vector DNA
was detected in semen.
Time Course of Vector-Mediated Expression of Wild-Type (M) AAT.
Vector-mediated expression of AAT was monitored using assays of
both total AAT (nephelometry) and wild-type (M) AAT (mAb-
based ELISA). Total AAT levels ranged from 3.1 to 6.0 M at day
1 and, except for subject 103 who had a transient increase of
Z-type AAT to 11 M concurrent with his bacterial epididymitis,
consistent with AAT being an acute-phase reaction protein, did not
change appreciably at subsequent visits (mean  SD ratio of
subsequent to baseline values, 100.8%  15.9%).
For the 4 subjects who had been receiving AAT protein aug-
mentation therapy, measurement of M-type AAT levels was com-
plicated by the reactivity of the M-specific mAb to residual infused
M-AAT protein therapy. This antibody has more than 500-fold
greater affinity for M-type AAT than for Z-type AAT, and
background M-specific AAT levels are therefore very low in PI*ZZ
individuals (mean  SD, 10.7  6.0 nM for 20 PI*ZZ individuals;
upper 99% confidence interval, 25 nM). However, because
weekly AAT protein augmentation therapy achieves peak serum
levels300M and nadir levels11M, the reactivity of the mAb
resulted in measured levels of M-specific AAT at day1 of 235 nM
and 358 nM in subjects 102 and 103, who had discontinued protein
augmentation therapy 28 days before vector administration, and
these levels progressively decreased until day 60 and remained
stable at 13 nM through day 90. Subjects 201 and 303, who had
discontinued protein augmentation therapy 56 days before vector
administration, had measured levels of M-specific AAT at day 1
of 33 nM and 18 nM, respectively, and these levels decreased to10
nM at day 14, after which they increased to a maximum of 28 nM
on day 90 in subject 201 and 48 nM on day 90 in subject 303 (Fig.
1). Serum M-specific AAT concentrations could not be determined
after day 90 in these patients because they had resumed protein
augmentation therapy.
Among the 5 subjects who were not receiving AAT protein
augmentation therapy, subject 101 received the lowest vector dose
and had no appreciable change in M-specific AAT levels. Among
those who received the intermediate vector dose, subject 202 had an
average pretreatment M-specific AAT level of 10 nM that increased
to 18 nM on day 30 and slowly decreased to pretreatment levels by
day 90, and subject 203 had an average pretreatment M-specific
AAT level of 11 nM that increased to 21 nM on day 60 and then
decreased to pretreatment levels by day 180 (Fig. 1). Among those
who received the highest vector dose, subject 301 had an average
pretreatment M-specific AAT level of 10 nM that increased to 43
nM on day 90 and remained above 40 nM for 1 year, and subject
302 had an average pretreatment M-specific AAT level of 8 nM that
increased to 18 nM on day 45 and then seemed to decrease to
Table 1. Demographic and baseline characteristics of subjects
Subject Age (y) Gender Weight (kg)
FEV1
(% predicted)
AAT protein
augmentation therapy
Prior rAAV2
vector dose (vg)
Dose of rAAV1 vector
in present trial (vg)
101 66 F 54.6 53.6 No 6.9  1012 6.9  1012
102 73 F 66.5 86.7 Yes — 6.9  1012
103 69 M 73.7 92.1 Yes 6.9  1012 6.9  1012
201 38 M 83.0 40.5 Yes — 2.2  1013
202 54 M 89.0 93.0 No 6.9  1013 2.2  1013
203 59 M 72.7 50.8 No 2.1  1013 2.2  1013
301 47 F 69.3 58.0 No — 6.0  1013
302 35 F 134.6 97.6 No — 6.0  1013
303 61 M 72.6 54.9 Yes — 6.0  1013
FEV1, forced expiratory volume in 1 s; vg, vector genome particles of rAAV2–AAT; F, female; M, male.
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pretreatment levels by day 90 but rose to 26 nM at day 180 and 33
nM at day 270 and day 365 (Fig. 1).
Time Course of Immune Responses to AAT and AAV and CK Levels.
Compared with a reference nonhuman primate positive control
serum assigned a value of 1 U/mL, anti-AAT antibody levels
measured by ELISA were very low (1 U/mL) at baseline and
remained very low without appreciable change after vector admin-
istration (Table S2). All subjects had anti-AAV antibodies detected
by ELISA that increased after vector administration (Table S2).
As expected, AAV neutralizing antibody levels at baseline dif-
fered between subjects who had or had not previously received a
rAAV2 vector (Table S3). Among the 4 subjects who had received
the rAAV2 vector, all had substantial neutralizing antibody titers
against AAV2 at baseline (range, 160 to 2,560) and lower baseline
titers against AAV1 (range,20 to 640). Among the 5 subjects who
not had received the rAAV2 vector, only 1 (subject 302) had a
baseline titer (640) against AAV2 and a low but detectable titer (20)
against AAV1. After i.m. injection of the rAAV1-AAT vector, all
subjects had a clear increase in neutralizing antibody titers against
AAV1 and a more variable increase in neutralizing antibody titers
against AAV2. There was no relationship between the neutralizing
antibody titer and the antibody titer measured by ELISA.
We also measured neutralizing antibody responses to AAV
serotypes 7, 8, and rh32.33 (Table S3). Consistent with previously
published results (16), antibodies to AAV7 and AAV8 were
detected at baseline infrequently (in 2 of 9 subjects, both of whom
had received the rAAV2 vector in a previous study) and antibodies
to AAVrh32.33 were not detected at baseline. After administration
of the rAAV1-CMV enhancer/chicken beta actin promotor-human
AAT (rAAV1-CB-hAAT) vector there was a modest increase in
antibody titers to AAV7 and AAV8 in 8 of 9 subjects and to
AAVrh32.33 in 6 of 9 subjects.
T cell immune responses to AAV and AAT were evaluated by
IFN-ELISPOT assay and were obtained retrospectively in 3 of the
first 4 subjects and prospectively in the last 5 subjects. When tested
more than 1 year after vector administration, subjects 101 and 103
had negative responses in an ex vivo ELISPOT assay but positive
responses in a cultured ELISPOT assay, and subject 201 had a
positive response in both the ex vivo ELISPOT assay and cultured
ELISPOT assay (Fig. 1). For the subjects evaluated prospectively,
the baseline ex vivo ELISPOT response was negative in all 5, and
the cultured ELISPOT response was positive in the 2 subjects (202
and 203) who had previously received the rAAV2-AAT vector and
negative in the other 3. All 5 developed positive IFN- ELISPOT
responses by day 14 in the cultured ELISPOT assay (Fig. 1) and by
day 14 in 4 and day 30 in the fifth in the ex vivo assay (Fig. 2). All
positive responses were directed against at least 2 of the 3 AAV
capsid peptide pools, remained positive at day 90, and were positive
at most intervening time points tested. Samples from later time
Fig. 1. Time course of vector-mediated AAT expression
and ELISPOT responses to AAV1 capsid peptides in (A)
cohort2and(B) cohort3. SerumM-specificAAT levelsare
plotted at the top of each panel and ELISPOT responses
are plotted at the bottom of each panel. For subjects 201
and 303, who had discontinued AAT protein augmenta-
tion therapy 56 days before vector administration and
resumed protein augmentation soon after day 90, AAT
values are not plotted on day1, day 3, or after day 90
but are described in the text. The day-365 sample for
subject 202 could not be tested owing to severe hemo-
lysis. ELISPOT responses are characterized as (negative
in both ex vivo and cultured assays),  (positive in cul-
tured assay but negative in ex vivo assay), or (positive
in both ex vivo and cultured assays). Samples for ELISPOT
analysis were not available beyond day 90 for subjects
202, 203, and 302.
Fig. 2. Time course of IFN-ELISPOT responses to pools of AAV1 capsid peptides
or controls. PBMC were obtained at 1 or 2 times before (pre1 and pre2) and at 14,
30, 45, 60, 75, and 90 days (D14 through D90, respectively) and 425 or 321 days
(Yr1) after vector administration and stimulated with each of 3 pools (A, B, and
C) of AAV1 capsid peptides (15-mers overlapping by 10 aa) or with a positive
controlpeptidepool (CEF).Responses thatweresignificantly increasedcompared
with medium alone (control) are indicated by an asterisk.
Brantly et al. PNAS  September 22, 2009  vol. 106  no. 38  16365
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points were available for subject 301 (at day 425) and subject 303
(at day 321) and were also positive. The magnitude of the response
to any individual pool was generally less than 200 spot-forming cells
(SFC) per 106 peripheral blood mononuclear cells (PBMC) for 4
subjects but was higher in subject 302 (e.g., the response to pool 3
was 330 SFC/106 PBMC at day 45, and the response to pool 2 was
428 SFC/106 PBMC at day 90).
We further investigated by polychromatic flow cytometry the
phenotype and functionality of the capsid-specific T cells from 2
subjects. PBMC from day 45 of subject 301 and day 81 of subject
302 were stimulated for 6 h with the AAV1 peptide library and
assessed simultaneously for 6 CD8 T cell functions, including
degranulation (CD107 and perforin), production of cytokines
(IFN-, TNF-, and IL-2), and chemokine (MIP-1) and cell-
surface markers (CD3, CD4, CD8, CD27, CD45RO, CD57, and
CCR7) to determine whether the capsid-specific T cells were
CD4 or CD8 cells and the functional profile of the responding
T cells. Subject 301 had a response to AAV1 capsid mediated by
CD4 cells that predominantly expressed TNF- and IL-2 (Fig. 3
A and B) and expressed markers indicative of central memory
phenotype (CCR7CD27CD45RO). Subject 302 had a re-
sponse to AAV1 capsid mediated by CD8 T cell that generally
seemed effector-like in functionality, with expression of perforin,
MIP-1, CD107a, and TNF- in various combinations, with rela-
tively little IL-2 and IFN- production (Fig. 3 C and D). All ex vivo
and cultured ELISPOT assays using AAT peptides were negative
at all time points tested.
T cell responses were also evaluated in all subjects using a
lymphocyte proliferation assay performed at baseline, day 14, and
day 90. For the AAV antigen, subject 202 had a stimulation index
(SI)1 at baseline and day 14 and an SI of 7.0 at day 90. In subject
301 the SI was 3.3, 0.7, and 2.6 at baseline and days 14 and 90,
respectively. All other subjects had negative responses (SI2.5) to
both AAV and AAT antigens at all time points tested.
Serum CK values were also assessed over time (Fig. 4). Only 5 of
the 36 values measured were above the reference range (170
U/L). Of these, 3 were baseline values, and the other 2 were from
1 of the subjects (102) who had had a high baseline value. None of
the values was greater than 1.5 times the upper limit of normal, and
none of the subjects for whom an effector T cell response was
demonstrated by day 14 had an elevated CK value after vector
administration.
Discussion
In this first-in-human phase 1 study, we have observed repro-
ducible expression of wild-type M-AAT protein from a cross-
packaged rAAV1–AAT vector after i.m. administration that was
sustained at subtherapeutic levels for at least 1 year in 2 subjects
and at least 90 days in the third subject in the 6.0 1013 vg dosage
level cohort, despite effector T cell responses that developed
within the first 14 days after vector delivery and persisted 90 days
Fig. 3. Evaluation of capsid-specific CD4 and CD8 T cell responses in subjects 301 and 302. (A) PBMC isolated at postinoculation day 45 were stimulated for 6 h
with peptides derived from AAV-1 capsid (15-mers overlapping by 10 aa, bottom row) or were unstimulated (top row). Frequencies shown represent viable responding
memory CD3CD4CD8- T cells within the respective quadrant gate after having gated out naïve cells (CCR7CD45RO-). (B) Bar chart representing the functionality
of AAV-specific CD4 T cells. (C) PBMC isolated at postinoculation day 81 were stimulated for 6 h with peptides derived from AAV-1 capsid (15-mers overlapping by
10 aa, bottom row) or were unstimulated (top row). Frequencies shown represent viable responding memory CD3CD8CD4- T cells within the respective quadrant
gate after having gated out naïve cells (CCR7CD45RO-). (D) Bar chart representing the functionality of AAV-specific CD8 T cells. Each bar represents the proportion
of the total response positive or negative for the respective functions shown in the key below the x axis. Only bars with positive responses above the 0.005% threshold
are shown.
Fig. 4. Serum CK levels before and after vector administration.
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or longer. The sustained nature of the expression of M-AAT,
along with the lack of CK elevation in the ELISPOT-positive
individuals, leads us to conclude that these responses are not
causing complete immune-mediated elimination of vector-
transduced myofibers.
Our studies should be considered in the context of the growing
body of clinical and preclinical studies evaluating the role of
capsid-specific T cells in rAAV gene therapy. The fact that capsid-
specific T cells can be generated after in vivo administration of
rAAV is well documented in many preclinical studies and in the
previously mentioned hemophilia and LPL deficiency human trials.
The controversial aspect of the capsid-specific T cell hypothesis is
whether the vector sensitizes transduced cells to become targets for
cytotoxic T lymphocyte (CTL)-mediated clearance by virtue of
MHC presentation of peptides from the input capsid protein. Our
study provides the most direct and extensive test of this hypothesis
because we observed sustained transgene expression for at least 1
year in 2 subjects (301 and 302) and at least 90 days in 2 subjects (201
and 303), and no CK elevations, despite the early onset and
persistence of T cell responses to AAV capsid peptides in all
subjects in whom these responses were measured. These data
clearly demonstrate that transgene expression can persist, despite
measured capsid-specific T cells, without apparent toxicity or
attenuation of transgene expression.
A number of hypothetical models might explain this finding.
Analysis of T cell function was limited owing to the availability of
cells and the low frequency of antigen-specific T cells. However, 1
of 2 subjects evaluated showed clear evidence of a CD8perforin
CTL response at 81 days after injection, and this subject (302)
demonstrated persistently positive transgene expression at 1 year
after vector administration. This would suggest that transduced
myofibers did not become CTL targets because they did not present
sufficient AAV1 capsid peptide on their cell surface. The rAAV
vectors used in these studies do not contain AAV capsid genes and
therefore cannot express capsid proteins de novo. Thus, it seems
quite plausible that transduced myofibers would not display AAV
capsid antigens.
The relationship between host and vector in the context of gene
therapy is complex and seems to vary considerably according to
vector type, serotype, dose, and route of administration, as well as
the species being studied. The complexity of these interactions has
confounded attempts to predict or model vector behavior in the
setting of phase 1 clinical trials. This complexity also comes into play
when comparing our data with that in the rAAV2–factor IX clinical
trial (14). Key differences between the trials include the serotype of
the vector and the route of administration. The rAAV–factor IX
study used a serotype 2 vector delivered to the liver by intraportal
injection and achieved serum factor IX concentrations up to 0.5
g/mL (10% of the normal 4 to 5g/mL). Our trial used a serotype
1 vector delivered to muscle by i.m. injection and achieved serum
AAT concentrations up to 2.6 g/mL (50 nM). It is also possible
that the AAT transgene itself, which has anti-inflammatory activity
(17), could have exerted an immunomodulatory effect.
Sustained expression of AAT was seen in 1 of 3 subjects at the
middle dosage level and all 3 subjects at the highest dosage level
tested. The other 2 subjects at these dosage levels had modest
increases in AAT expression that were not sustained (although
subject 203 had elevated M-specific AAT in a sample at 1 year after
treatment). The lack of sustained expression may merely reflect the
fact that the expression levels were only modestly above baseline,
and even a slight decline would result in an inability to detect
continuing low-level expression. The time to peak expression was at
least 90 days, which is longer than would have been predicted from
nonclinical studies.
The serum neutralizing antibody responses to AAV1 in this trial
were consistent and predictable. Some individuals developed high
titers of neutralizing antibodies to distinct AAV serotypes such as
AAV7, -8, and -32.33, which is unexpected on the basis of animal
immunization studies that indicate few shared B cell epitopes
between these AAVs (18, 19). The diversity in the breadth of
serologic responses to intramuscular AAV1 is quite striking, as
illustrated by the high-dose group in which 2 subjects (301 and 302)
showed a broad response and 1 (303) showed a narrow sero-specific
response. It is possible that the endogenous flora of latent/persistent
AAVs and resulting immune responses contribute to these unex-
pected findings. This also suggests that the strategy of using a
sequence of vectors with different serologic capsids to overcome the
humoral immune response of the first vector may not work in some
individuals.
Importantly, none of the subjects developed antibody or T cell
responses to the AAT transgene. This is consistent with clinical
experience with AAT augmentation therapy, in which immune
responses to AAT have not been observed.
Evaluation of vector biodistribution in this clinical study was
limited to collection of blood and semen samples. The detection of
vector DNA in blood during the first week after injection, with rapid
clearance to low or undetectable levels at day 14 or day 90, is
consistent with results from preclinical studies in mice and rabbits
(13). In rabbits, low levels of vector DNA were found in semen
during the first week after injection but not at days 21, 60, or 90, and
in the clinical trial no vector DNA was found in semen from any of
the men from whom semen samples were available.
The study design originally required subjects receiving AAT
augmentation therapy to discontinue that therapy 28 days before
vector administration, on the basis of published data indicating that
the elimination half-life of infused AAT is 2 to 3 days (20, 21).
Although this resulted in total AAT levels that were well within the
expected range for PI*ZZ subjects at day 1, substantial residual
levels of M-type AAT were detected in these subjects, and the
‘‘washout’’ period was extended to 56 days for subjects enrolled in
cohorts 2 and 3. However, 2 such subjects had slightly elevated
M-type AAT levels at day 1 and day 3. A recent report suggests
that the elimination half-life of infused AAT may be as high as 8 or
9 days (22), and the ‘‘washout’’ period should probably be extended
to 90 days in future rAAV–AAT gene transfer studies.
With regard to the potential for positive clinical effects from
rAAV1–AAT gene therapy, it must be pointed out that the
expression levels observed in this study are more than 200-fold
below the established therapeutic target (11 M) for AAT aug-
mentation therapy. However, the positive safety profile and pro-
longed duration of transgene expression in this study suggests that
this route of delivery remains promising for future product devel-
opment, including the likely need for a substantial dosage increase.
In the highest dosage level cohort, the immune responses detected
in these subjects were not linked to clinically significant safety
issues. Thus, there does not seem to be any indication for pharma-
cologic immune suppression or other alteration of the clinical
protocols as the clinical trial program for rAAV1–AAT continues
in the near future.
Methods
Good Manufacturing Practices Vector Production and Purification. The AAV–AAT
expression cassette contains AAV2 inverted terminal repeats on either end of the
construct with a CB enhancer/promoter sequence (containing a cytomegalovirus
immediate early enhancer/chicken -actin promoter with a hybrid chicken -ac-
tin/rabbit -globin intron) followed by the human AAT cDNA and a bovine
growth hormone polyadenylation signal (13). Vector was packaged and purified
under current Good Manufacturing Practices using a published cotransfection
techniqueinHEK-293cellswiththepKRAPpackagingplasmid,whichencodesthe
other Ad helper genes and the AAV1 repand capgenes (23). Downstream vector
purification was performed using an all-column purification method (24, 25).
Clinical Protocol and Informed Consent. Subjects receiving AAT augmentation
therapy were asked to discontinue that therapy 28 days (cohort 1) or 56 days
(cohorts 2 and 3) before vector administration and not resume until at least 11
weeks after vector administration. Subjects returned to the Clinical Research
Center on day 1 for repeated studies, and the conformity of each potential
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subject with inclusion and exclusion criteria was confirmed. (For more details
refer to SI Text.)
Injection Procedure. The deltoid muscle of the nondominant arm (left arm for
right-handedindividualsandviceversa)waschosenasthesiteof injection.Before
vector injection, a baseline computed tomography scan of the chest and upper
extremity was performed to assess baseline morphology and rule out underlying
abnormalities of the upper extremity. Doppler ultrasound was performed over
the potential injection site immediately before and during the injection to avoid
vascular structures with observable flow. The needle was also directly visualized
and the outflow of vector visualized with Doppler ultrasound in real time. The
dose was administered in a constant 9.9-mL volume, regardless of vector dose,
using lactated Ringers solution to dilute the vector to the proper concentration.
At the time of the injection, 9 separate injections of 1.1 mL each were injected
slowly over 1 min each.
Biodistribution Assays. Blood samples (and semen when available) were ob-
tained at screening and on days 1 (blood only), 3, 14, and 90. DNA was extracted,
and vector sequences were detected using Taqman real-time PCR techniques
with a previously published primer/probe set directed against a vector-specific CB
promoter sequence (26, 27). All samples were tested in duplicate, with a third
sample containing a positive spike-in control. The technique has a sensitivity of
100 copies per microgram of input DNA.
Measurement of Total and Wild-Type (M-Specific) AAT. Total AAT was measured
using a clinically approved nephelometry method, an automated assay in which
polyclonal rabbit anti-AAT antibody (Siemens Healthcare Diagnostics) is mixed
with serum and the resulting antigen-antibody complexes are detected by light
scattering in a nephelometer (Dade-Behring Nephelometer II; Siemens). M-
specific AAT was measured by ELISA, monoclonal antibody was developed in a
standard fashion by injecting mice with highly purified PI M1M1 AAT, isolating
hybridclonesandidentifyingclonesthatmadeantibodytoMbutnotZAATusing
a dot blot. The M-specific ELISA is a standard double sandwich assay, primary
antibody is monoclonal to M AAT, and secondary is rabbit antihuman AAT
(Dako). Assays were run on a SPECTRAmax (Molecular Devices) plate reader using
a highly purified PI M1M1 AAT (Athens Research). The assay was validated for
accuracy, reproducibility, selectivity, lowest limit of quantification, and stability
(Fig. S1). Dilutions of serum are added to wells coated with this mAb at 167 ng/mL
and antigen–antibody complexes detected using a polyclonal rabbit antihuman
AAT at 20 ng/mL followed by a peroxidase-conjugated goat antirabbit Ig, with
O-phenylenediamine added for colorimetric analysis. The assay is validated for
accuracy, repeatability, and precision using a broad range of concentrations and
is also validated for serum stability at various temperatures ranging from 24 °C to
80 °C. The lower limit of quantification for this assay is 8.8 pM, with selectivity
and reproducibility at the lower limit of detection90%.
Antibody Responses. Serum was obtained at screening and on days 14 and 90 for
measurement of neutralizing antibodies to AAV and antibodies to AAT and AAV
by ELISA. Neutralizing antibodies were measured as previously described (28).
Anti-AAV2 and anti-AAT antibodies were assayed by ELISA as previously de-
scribed (11). In the case of the anti-AAT antibody assay, the positive control serum
was taken from a baboon immunized against human AAT in a prior study (27).
Cellular ImmuneResponses.BloodwascollectedandPBMCseparatedat screening
and on days 14 and 90 for measurement of lymphocyte proliferative responses to
AAV and AAT antigens as previously described (26, 29). For more details refer to
SI Text.
In Vitro Stimulation and Staining of Cells and Polychromatic Flow Cytometry.
Costimulatory antibodies (anti-CD28 and CD49d, 1 g/mL; BD Biosciences), mo-
nensin (Golgistop, 0.7 l/mL; BD Biosciences), brefeldin A (10 g/mL; Sigma-
Aldrich), and anti-CD107a–PE-Cy5 were added and the cells aliquoted at 1 mL to
a tube containing 2 g of AAV1 peptide libraries. A positive control (Staphylo-
coccusenterotoxin B, 1g/mL; Sigma-Aldrich) and unstimulated negative control
were included in each assay. After fixation, cells were washed twice in perm
buffer, stained with antibodies against intracellular markers, and then washed,
fixed with PBS containing 1% paraformaldehyde, and stored at 4 °C until analysis
(performed within 24 h). Analysis was performed using FlowJo software
(TreeStar) as previously described (31).
Long-Term Follow-Up. Upon completion of this study, each subject will be
followed annually for an additional 4 years (5 years total) and questioned about
the development of any delayed malignant, neurologic, immunologic, hemato-
logic, or other adverse events.
Statistical Analysis. All ELISPOT data were compared using an unequal variance
two-tailed Student’s t test. Differences were considered statistically significant if
P 0.05.
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Fig. 2. Transformants releasing EC suffered less damage than control lines when EPNs were present. (A) Root damage measured on plants that had received
neither WCR eggs nor nematodes was minimal, and there was no difference between transformed and nontransformed plants (n 5, P 0.87). (B) Root damage
on plants that received only WCR eggs, but no nematodes, was substantial. Again, no significant difference was found between the transformed and
nontransformed plants (n 5, P 0.18). (C) In plots that received WCR eggs andH.megidis, roots from transformed plants (pooled) had significantly less damage
than roots from control lines (n 30, P 0.007). Approximately one-quarter of the transformed plants were found not to emit EC. Removing these plants from
the statistical analysis did not significantly affect the results. The letters above the bars indicate significant differences within a graph. Error bars indicate standard
errors.
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